---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-121446"
form_type: "8-K"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:15:49.520042+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers

## Summary
- IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.
- Co-developed with Celltrion; phase 1 start expected in 1H 2026 pending FDA clearance.
- Preclinical data presented at AACR 2025 and SITC 2025 showed selective activity in HER2-high tumor models.
- First IND submission by Abpro for a solid tumor indication, advancing its immuno-oncology pipeline.
- Phase 1 study will evaluate safety, PK, and preliminary efficacy in dose-escalation and expansion cohorts.

## SEC filing metadata
- accession: 0001213900-25-121446
- form_type: 8-K
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000121390025121446/0001213900-25-121446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000121390025121446/ea0269613-8k_abpro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-121446
- JSON: https://secwatch.observer/filing/0001213900-25-121446.json
- Plain text: https://secwatch.observer/filing/0001213900-25-121446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.